|Bid||49.20 x 1200|
|Ask||49.30 x 900|
|Day's Range||47.30 - 49.40|
|52 Week Range||22.65 - 49.45|
|PE Ratio (TTM)||24,575.00|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Surmodics, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for SRDX for clues.
On a per-share basis, the Eden Prairie, Minnesota-based company said it had profit of 11 cents. Earnings, adjusted for non-recurring gains, came to 7 cents per share. The drug delivery technology company ...
Here we analyze the financials and fundamental factors of Haemonetics (HAE) and Surmodics (SRDX) to decide which is a better investment option.
Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips
Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.
On February 27, 2018, Abbott Laboratories (ABT) and Surmodics (SRDX) announced that the two companies have entered an agreement for the commercialization rights of Surmodics’ SurVeil DCB (drug-coated balloon) for the treatment of superficial femoral artery. As per the agreement, Abbott Laboratories will gain exclusive commercial rights for the SurVeil DCB, which is currently in clinical trials. Surmodics will supply the device to Abbott once approved.
Abbott (ABT) gains traction from its newly acquired rights over the SurVeil drug-coated balloon, which shows greater potential for capturing the market compared with traditional devices.
Med-tech firm Surmodics Inc. has landed a licensing deal with health care giant Abbott Laboratories Inc. that could be worth up to $92 million, the companies announced Tuesday. Eden Prairie-based Surmodics will exclusively license its SurVeil drug-coated balloon device to Abbott (ABT). Surmodics is testing the device as a treatment for peripheral artery disease.
The Eden Prairie, Minnesota-based company said it had a loss of 12 cents per share. Earnings, adjusted for pretax expenses and non-recurring costs, were 10 cents per share. The drug delivery technology ...
Surmodics' (SRDX) top line benefits from strong sales in Medical Device and IVD businesses. However, foreign currency is a headwind.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for SurModics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Surmodics Inc (NASDAQ:SRDX) files its latest 10-K with SEC for the fiscal year ended on September 30, 2017.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives SurModics, Inc. a score of 67. Our analysis is based on comparing SurModics, Inc. with the following peers – Nektar Therapeutics, Thermo Fisher Scientific Inc., Heron Therapeutics Inc, Abbott Laboratories, pSivida Corp., Johnson & Johnson, PerkinElmer, Inc., Enzo Biochem, Inc., Alkermes Plc and Agilent Technologies, Inc. (NKTR-US, ... Read more (Read more...)
Based on the latest analyst prediction, Surmodics Inc (NASDAQ:SRDX) is estimated to immensely contract its earnings by beyond -150% next year. Presently, with an EPS of $0.298, we can expectRead More...